MedTrace Logo

Sequence Towards Remission in Depression

NCT01628783 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2012-06-27

No results posted yet for this study

Summary

In this study the investigators use clinical, biological and imaging markers to develop predictive markers for remission from depression. The investigators compare individuals who have received placebo to individuals who have received 10 mg of escitalopram for one week. In this double-blind, randomized study the investigators a) compare the groups to observe the short-term effects of escitalopram and b) study the predictive value of these observations with respect to remission. Measures include, but are not restricted to, limbic emotional reactivity as assessed by fMRI, emotional processing, emotional memory, autobiographical memory.

Conditions

Interventions

DRUG

escitalopram 10 mg

orally once daily

DRUG

Placebo

once daily

Sponsors & Collaborators

  • Academy of Finland

    collaborator OTHER

  • Jesper Ekelund

    lead OTHER

Principal Investigators

  • Erkki Isometsä, MD-PhD · University of Helsinki

  • Jesper Ekelund, MD-PhD · University of Helsinki

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-12-31
Completion
2015-10-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01628783 on ClinicalTrials.gov